173 related articles for article (PubMed ID: 36103824)
1. BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer.
Yan G; Luna A; Wang H; Bozorgui B; Li X; Sanchez M; Dereli Z; Kahraman N; Kara G; Chen X; Zheng C; McGrail D; Sahni N; Lu Y; Babur O; Cokol M; Lim B; Ozpolat B; Sander C; Mills GB; Korkut A
Cell Rep; 2022 Sep; 40(11):111304. PubMed ID: 36103824
[TBL] [Abstract][Full Text] [Related]
2. Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma.
Tseng HY; Dreyer J; Emran AA; Gunatilake D; Pirozyan M; Cullinane C; Dutton-Regester K; Rizos H; Hayward NK; McArthur G; Hersey P; Tiffen J; Gallagher S
Int J Cancer; 2020 Oct; 147(8):2176-2189. PubMed ID: 32249419
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of EGFR pathway promotes the cytotoxicity of ABT-263 in human leukemia K562 cells by blocking MCL1 upregulation.
Lee YC; Wang LJ; Huang CH; Chiou JT; Shi YJ; Chang LS
Biochem Pharmacol; 2020 Aug; 178():114047. PubMed ID: 32446890
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer sub-types display heterogeneity in gene amplification and mRNA expression of the anti-apoptotic members of BCL2 family.
Voutsadakis IA
Gene; 2023 Mar; 857():147179. PubMed ID: 36627096
[TBL] [Abstract][Full Text] [Related]
5. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
[TBL] [Abstract][Full Text] [Related]
6. Molecular alterations in anti-apoptotic BCL2 family proteins in breast cancer cell line models, drug sensitivities and dependencies to guide the development of BCL2 inhibitors.
Voutsadakis IA
Gene; 2022 Dec; 847():146881. PubMed ID: 36100115
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
8. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
Arai S; Jonas O; Whitman MA; Corey E; Balk SP; Chen S
Clin Cancer Res; 2018 Nov; 24(21):5458-5470. PubMed ID: 30021909
[No Abstract] [Full Text] [Related]
9. Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer.
Farrugia MK; Sharma SB; Lin CC; McLaughlin SL; Vanderbilt DB; Ammer AG; Salkeni MA; Stoilov P; Agazie YM; Creighton CJ; Ruppert JM
Cell Death Dis; 2015 Mar; 6(3):e1699. PubMed ID: 25789974
[TBL] [Abstract][Full Text] [Related]
10. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.
Qi L; Zhang B; Zhang S; Ci X; Wu Q; Ma G; Luo A; Fu L; King JL; Nahta R; Dong JT
Oncotarget; 2017 May; 8(22):36054-36066. PubMed ID: 28415602
[TBL] [Abstract][Full Text] [Related]
11. Loss of MCL1 function sensitizes the MDA-MB-231 breast cancer cells to rh-TRAIL by increasing DR4 levels.
De Blasio A; Pratelli G; Drago-Ferrante R; Saliba C; Baldacchino S; Grech G; Tesoriere G; Scerri C; Vento R; Di Fiore R
J Cell Physiol; 2019 Aug; 234(10):18432-18447. PubMed ID: 30912136
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.
Santer FR; Erb HH; Oh SJ; Handle F; Feiersinger GE; Luef B; Bu H; Schäfer G; Ploner C; Egger M; Rane JK; Maitland NJ; Klocker H; Eder IE; Culig Z
Oncotarget; 2015 Mar; 6(8):6105-22. PubMed ID: 25749045
[TBL] [Abstract][Full Text] [Related]
13. ELP-dependent expression of
Cruz-Gordillo P; Honeywell ME; Harper NW; Leete T; Lee MJ
Sci Signal; 2020 Nov; 13(658):. PubMed ID: 33203722
[TBL] [Abstract][Full Text] [Related]
14. β2-adrenoreceptor Signaling Increases Therapy Resistance in Prostate Cancer by Upregulating MCL1.
Hassan S; Pullikuth A; Nelson KC; Flores A; Karpova Y; Baiz D; Zhu S; Sui G; Huang Y; Choi YA; D'Agostino R; Hemal A; von Holzen U; Debinski W; Kulik G
Mol Cancer Res; 2020 Dec; 18(12):1839-1848. PubMed ID: 32928910
[TBL] [Abstract][Full Text] [Related]
15. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.
Lee KM; Giltnane JM; Balko JM; Schwarz LJ; Guerrero-Zotano AL; Hutchinson KE; Nixon MJ; Estrada MV; Sánchez V; Sanders ME; Lee T; Gómez H; Lluch A; Pérez-Fidalgo JA; Wolf MM; Andrejeva G; Rathmell JC; Fesik SW; Arteaga CL
Cell Metab; 2017 Oct; 26(4):633-647.e7. PubMed ID: 28978427
[TBL] [Abstract][Full Text] [Related]
16. MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation.
Arai S; Varkaris A; Nouri M; Chen S; Xie L; Balk SP
Elife; 2020 Jun; 9():. PubMed ID: 32484436
[TBL] [Abstract][Full Text] [Related]
17. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
18. EGFR-independent EGFR-mutant lung adenocarcinoma cells depend on Bcl-xL and MCL1 for survival.
Hirai S; Tada M; Yamaguchi M; Niki T; Sakuma Y
Biochem Biophys Res Commun; 2020 May; 526(2):417-423. PubMed ID: 32223928
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
[TBL] [Abstract][Full Text] [Related]
20. miR-107 activates ATR/Chk1 pathway and suppress cervical cancer invasion by targeting MCL1.
Zhou C; Li G; Zhou J; Han N; Liu Z; Yin J
PLoS One; 2014; 9(11):e111860. PubMed ID: 25386925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
